Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience
about
Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsEngineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapyAutophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy.Comparative cost models of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine.SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathwayAutoimmunity as a double agent in tumor killing and cancer promotion.Mechanism of synergistic effect of chemotherapy and immunotherapy of cancer.Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response.The chemokine system in allogeneic stem-cell transplantation: a possible therapeutic target?Future perspectives: should Th17 cells be considered as a possible therapeutic target in acute myeloid leukemia patients receiving allogeneic stem cell transplantation?High-dose etoposide in allogeneic stem cell transplantation.Heat shock protein 70 - the next chaperone to target in the treatment of human acute myelogenous leukemia?Potential approaches for more successful dendritic cell-based immunotherapy.Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
P2860
Q24633763-FE1DBCA5-C8F1-42C5-ACC9-13BB0205A351Q28485036-2210FBEE-7EB9-4869-B04C-900FEBAA7284Q30402590-74D8AB15-7739-4FE5-B0A1-1C89EC495D0FQ36884670-1BC7DE34-1340-4445-A0B8-123E75BAFC01Q37541654-B9EFB0FA-FF3C-493C-A24D-1D8E20D4C0F1Q37642271-1071A079-7FA4-48F8-B29F-4A3A0B1282F6Q37803144-09884B03-B48A-47C6-88E4-4EAAC1EDA73DQ37868974-54E61806-DD84-4FC0-845E-07609C494FD1Q37917774-29AE30EB-033B-47EC-8C45-32D5E3BAF80BQ37937045-EB2781D5-7B3B-4ED9-A612-364A174FCC63Q37944472-2F33FC84-4D0E-49AE-A760-BB91AD900CC3Q38051016-64B43B02-AA10-4D68-9052-8E7289F9E7ADQ38222563-04901A06-3CC1-461A-B4B9-2F00564232AEQ38305650-7BFAF46D-7048-4292-9235-9D36B94B1302Q41973082-26B7F603-944F-4FE3-86F0-C34C5186032FQ48508291-5387CF9F-11FB-49D5-87CD-0F94AA015F3D
P2860
Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Combination of intensive chemo ...... : the hematological experience
@en
Combination of intensive chemo ...... the hematological experience.
@nl
type
label
Combination of intensive chemo ...... : the hematological experience
@en
Combination of intensive chemo ...... the hematological experience.
@nl
prefLabel
Combination of intensive chemo ...... : the hematological experience
@en
Combination of intensive chemo ...... the hematological experience.
@nl
P2093
P2860
P356
P1476
Combination of intensive chemo ...... : the hematological experience
@en
P2093
Elisabeth Ersvaer
Knut Liseth
Tor Hervig
Øystein Bruserud
P2860
P304
P356
10.1155/2010/692097
P577
2010-06-02T00:00:00Z